CELL AND GENE THERAPY

mRNA Victoria and Ginkgo Bioworks Announce Partnership to Grow the Bioeconomy & International Biosecurity Capabilities

Ginkgo Bioworks, mRNA Victoria | November 18, 2021

mRNA Victoria, the agency of the Australian State of Victoria Government charged with building the State's mRNA manufacturing and research capability, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced a partnership to support vaccine development, biosecurity initiatives, and the application to Ginkgo's platform in the pharmaceutical and biotech, food and agriculture, and mining and bioremediation/recycling sectors in Australia. As the first step in the partnership, Ginkgo will establish an office in Melbourne in what is hoped to be a future long-term business expansion within Australia.

Ginkgo's synthetic biology platform infrastructure and expertise brings critical capability to Victoria's biotech sector, and adds significant momentum to the State's rapidly growing biotechnology ecosystem. Ginkgo's cell programming capabilities have supported innovations in diagnostics and vaccine design and manufacturing, as well as ongoing research and development of innovative products such as living medicines, therapeutic proteins, and gene and cell therapies. Further, the company has established one of the largest nationwide COVID testing platforms in the United States, helping communities across the country keep kids in classrooms and COVID out. The company has also established an Airport Biosurveillance Program in collaboration with XpresCheck and the Centers for Disease Control and Prevention (CDC).

"Melbourne is one of the leading biomedical research communities in the world. We have to forge international collaborations like this because, as we have all learned, biology doesn't respect borders. We are incredibly excited to work with mRNA Victoria and hope to expand further into the Australian market,"

said Matt McKnight, Chief Commercial Officer, Ginkgo Bioworks

Victoria is a leader in mRNA research and manufacturing in Australia, with the nation's most sophisticated and largest mRNA ecosystem and commercialization capability. Through mRNA Victoria, the Victorian Government will continue to attract world leading biotech innovators to invest in Victoria, creating new jobs and fostering innovation in novel RNA treatments.

"Victoria has a strong RNA ecosystem and is ideally placed to develop a sophisticated supply chain with critical capability from clinical development to the establishment of onshore mRNA manufacturing to the critical biosecurity technologies that enable us to reopen borders and get back to our lives," said Jaala Pulford, Victoria's Minister for Innovation, Medical Research and the Digital Economy.

About mRNA Victoria
The State of Victoria is the home of Australia's biotech community with a globally recognized research sector including the country's leading mRNA researchers and existing capabilities in medtech, biotech, pharmaceutical and advanced manufacturing.  mRNA Victoria is the Australian State of Victoria Government agency charged with building a world-class mRNA manufacturing and research capability.  It leads the engagement and partnership with domestic and international companies, researchers, and other stakeholders in the mRNA ecosystem, and its investments and programs accelerate the growth of mRNA technology's scientific, commercial, and life-saving potential. 

About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. 

Forward-Looking Statements of Ginkgo Bioworks
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential of Ginkgo's biosecurity capabilities and partnership with mRNA Victoria. These forward-looking statements generally are identified by the words "believe," "project," "potential," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the effect of the business combination with Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo's employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo related to its business combination with Soaring Eagle, (iv) volatility in the price of Ginkgo's securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo's business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, and (vi) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the "Risk Factors" section of Ginkgo's quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the "SEC") on November 15, 2021 and other documents filed by Ginkgo from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Ginkgo does not give any assurance that it will achieve its expectations.

Spotlight

Every three seconds someone in the world develops dementia. Dementia affects 50 million people, costing the global economy over US$1 trillion in 2018. By 2030, there will be an estimated 82 million people with dementia, placing an unprecedented strain on health systems around the world.


Other News
RESEARCH

Institute for Bioscience and Biotechnology Research Receives $16.8 M Investment from the National Institute of Standards and Technology

Institute for Bioscience and Biotechnology Research | January 14, 2022

The Institute for Bioscience and Biotechnology Research announces a newly funded five-year cooperative agreement with the National Institute of Standards and Technology headed by the Co-Directors of IBBR, Dr. David J. Weber (PI) and Dr. John Marino This award provides more than $3.3 million each year to support groundbreaking research, including technology and standards development that will impact vaccine and therapeutic discovery and development, and to improve access to life-saving treatments for addressing other crucial health challenges. IBBR is a joint research enterprise of the University of Maryland, College Park, the University of Maryland, Baltimore and NIST. Research born out of this new cooperative agreement will be applied to accelerating the development and manufacturing of new pharmaceutical and vaccine approaches including cell and gene therapies and mRNA vaccines. This type of bioscience and bioengineering research will enable robust and rapid responses to pandemics and help remove obstacles to care and treatment related to rare childhood diseases and complex cancers. "Trusting in and funding research makes it possible to find solutions to address major health and scientific challenges, and to prepare for the unknown. UMB has invested heavily in operational support and high-end instruments for IBBR in support of the NIST relationship. I am very pleased to see that the long-standing NIST collaboration will continue." Bruce E. Jarrell, MD, FACS, President of the University of Maryland, Baltimore As part of the new agreement, NIST provided state-of-the-art equipment for the "IBBR Commons"—a highly sophisticated research space shared with researchers throughout Maryland and the nation. For example, NIST recently partnered with Maryland to establish the Maryland Center for Advanced Molecular Analysis (M-CAMA) that established new cryo-electron (cryoEM) instruments and facilities to be used by NIST and researchers in Maryland for the timely development of new therapies and vaccines. "IBBR has long provided the critical link necessary to bring together researchers across disciplines to address major health challenges and help strengthen the state's economic base in bioscience and biotechnology," said Darryll J. Pines, Ph.D., President of the University of Maryland, College Park. "I am so pleased this collaboration between NIST and the University of Maryland, Baltimore and the University of Maryland, College Park remains strong, and I look forward to seeing the innovations it will lead to in the future." IBBR was established by the University System of Maryland Board of Regents in 2010, building on and integrating previous partnerships between the University of Maryland and NIST that date back to 1984. The institute connects dozens of experts from interrelated fields of study with the common goal of accomplishing world-class interdisciplinary research that can lead to real-world advances like drug discovery, more effective vaccines, and disease prevention and treatment. "Achieving truly groundbreaking results in fields like bioscience and biotechnology requires a wide array of resources, perspectives and expertise—from pharmaceutical and biotech companies to academic and government institutions, to foundations and NGOs," said Jennifer King Rice, Ph.D., Senior Vice President and Provost of the University of Maryland, College Park. "What makes IBBR so unique and impactful is its ability to stand in the center of this circle of voices as the catalyst for collaborative and impactful work." "Having this important cooperative agreement with NIST enables us to develop and share the most sophisticated and advanced instrumentation for use in the discovery, development and manufacturing of safe and effective new medicines to treat human disease—including, most recently, for COVID19," said E. Albert Reece, MD, Ph.D., MBA, Executive Vice President for Medical Affairs at the University of Maryland, Baltimore and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the University of Maryland School of Medicine. About IBBR IBBR is a joint research enterprise of the University of Maryland, College Park, the University of Maryland, Baltimore, and the National Institute of Standards and Technology. IBBR brings together critical elements necessary to inspire transformative discoveries in the field of bioscience and biotechnology and provides innovative solutions to major scientific and engineering challenges important to society. IBBR researchers seek to advance the fields of biomedical research, therapeutic development, biomedical manufacturing, and state-of-the-art measurement technologies, to support accelerated delivery of safe and effective medicines to the public. IBBR is financially supported in part by the University of Maryland Strategic Partnership: MPowering the State, an initiative designed to achieve innovation and impact through collaboration.

Read More

INDUSTRIAL IMPACT

c-LEcta Announces That It Has Reached Agreement to Be Acquired by Kerry Group

c-LEcta | February 16, 2022

c-LEcta, a leading biotechnology company in enzyme engineering and bioprocess development, has announced that it has reached an agreement with Kerry Group for it to acquire a majority shareholding of the company. Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets. This strategically compelling combination will accelerate Kerry’s innovation capabilities in enzyme engineering, fermentation and bio-process development while also enabling c-LEcta to fufill its long term growth potential. “We are very happy to join Kerry group and their global presence in the food and pharmaceutical sectors gives us access to additional markets. At the same time, their expertise in ingredient technologies and applications is a perfect fit as we continue to drive our growth potential in the future. We will continue to collaborate with our existing industry partners and will of course continue to produce and distribute our products for our valued customers.” Dr Marc Struhalla, founder and CEO of c-LEcta Thomas Pfaadt, CFO of c-LEcta adds: “We want to thank our previous investors for the great cooperation over the past years. Without their contribution, such a development would not have been possible. Together, we have achieved a lot and we are thankful for their support.” Commenting on the agreement with c-LEcta, Dr Albert McQuaid, Chief Science and Technology Officer of Kerry, said: “The food and pharmaceutical industries are on the cusp of a new wave of innovation where new developments in biotechnology, synthetic biology and precision fermentation are radically transforming these sectors. c-LEcta is a leader in these new technologies, which includes fermentation-based products such as disruptive new enzymes, and the strategically compelling combination with Kerry will accelerate our innovation capabilities in enzyme engineering, fermentation and bio-process development. Our broad market reach across food and pharma markets, combined with our deep enzyme applications expertise and integrated ingredient technology design, will enable and accelerate the growth potential of c-LEcta’s strong portfolio and technology capabilities while also supporting us in the creation of tastier, more sustainable and healthier products.” About c-LEcta c-LEcta is a leading biotechnology company located in Leipzig, Germany. The company has established itself as a leading player in the realisation of high-value biotechnology products for regulated markets, either as in-house development or in close cooperation with the industry. c-LEcta innovation capability delivers cost-efficient and sustainable production processes, creating growth opportunities across existing and new markets. About the Kerry Group Kerry is a world-leading taste and nutrition partner for the food, beverage, and pharmaceutical markets and with its broad portfolio of ingredient solutions reaches more than one billion customers worldwide. Together with their customers, Kerry develops innovative products with great taste, improved nutritional value, and higher functionality, while having a better impact on the environment. Thanks to their leading consumer knowledge, their global RD&A team with more than 1,100 food scientists, and their comprehensive, global presence, Kerry can overcome the complex challenges of their customers with differentiated solutions. Kerry is willing to be a valued partner for their customers and to create a world of sustainable nutrition.

Read More

INDUSTRIAL IMPACT

Nexeo Plastics and Earth Renewable Technologies Sign Agreement to Distribute BioCompounds in North America

Nexeo Plastics | March 02, 2022

Nexeo Plastics, a leading global thermoplastics resin distributor, has announced an agreement with Earth Renewable Technologies, Inc. (ERT), a biotechnology company, to distribute ERT’s BioCompounds in Canada and the United States. “We are extremely pleased to collaborate with ERT to increase the slate of sustainable products we offer our customers. ERT’s BioCompounds complement the products we already carry and help us close the gap in our renewable solutions line card.” Arturo Hoyo, Nexeo Plastics’ Vice President of Product Line Management Compostable, biobased and/or biodegradable, ERT’s plant-based BioCompounds perform like conventional plastics and are often ideal for a wide range of uses, including single-use and one-time niche applications, such as bags, bottles and cutlery. “We want to make the world more sustainable by improving the availability of sustainable materials that can perform like plastic,” said ERT President Kim Fabri. “Nexeo Plastics’ reach in North America, their understanding of the value of sustainable material, and their growing portfolio of sustainable products makes them an ideal partner for us.” About Nexeo Plastics Nexeo Plastics is a leading global thermoplastic resins distributor, representing quality products from world-class suppliers, and serving a diverse customer base across North America, Latin America, Europe, Middle East, Africa and Asia. From material selection assistance to identifying supply chain and inventory solutions, we go beyond traditional logistics to provide value-added services across many industries, including automotive, healthcare, packaging, wire and cable, 3D printing and more. About Earth Renewable Technologies Earth Renewable Technologies, Inc. (ERT) was founded in 2009 with the mission of replacing plastic packaging with biodegradable materials. ERT patented SFRP (Short Fiber Reinforced Polymer), a pioneering technology capable of drastically modifying the performance of biopolymers and delivering previously unknown applications for these materials. Since then, the company has been introducing new technologies to the market, revolutionizing the biopolymer market and allowing companies to truly move towards a circular economy.

Read More

INDUSTRIAL IMPACT

O2 Invests in Modular Devices, Inc.

O2 Investment Partners ( | January 24, 2022

O2 Investment Partners announced that it has partnered with Modular Devices, Inc. and its President & CEO, Greg Mink, to support the Company’s continued growth. Terms of the deal were not disclosed. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases to healthcare systems of all sizes. MDI is the only company offering modular cath labs as a stock-standard product available for rent. The Company’s cleanroom division serves the pharmaceutical, biotechnology, and manufacturing sectors by providing standard and customized pre-certified ISO and USP compliant units for lease and for sale. MDI is headquartered in Indianapolis, IN. “We are experiencing rapid growth and feel that we are at a key moment in our company’s evolution. I believe that O2 is the optimal partner to continue our track record of success and capitalize on MDI’s growth initiatives in the healthcare, pharmaceutical, and biotechnology markets.” Greg Mink, President & CEO of MDI Pat Corden at O2 commented, “Greg and the MDI team have built a very exciting business with a reputation for delivering best-in-class products and services to its customers. O2 is excited to partner with MDI and looks forward to supporting the business in its next stage of development. We would also like to thank our financial partner, Maranon Capital for their support in this transaction.” MDI is the sixth platform investment for O2’s most recent fund, O2 Investment Partners Fund III. O2 and MDI are aggressively pursuing M&A opportunities to expand the Company’s product and service offering. About Modular Devices, Inc. Founded in 1987, Modular Devices, Inc. is a leading provider of mobile and modular medical imaging equipment labs and cleanroom solutions throughout the United States. MDI’s medical imaging solutions offer various imaging modalities through short- and long-term leases to healthcare systems of all sizes. MDI is the only company offering modular cath labs as a stock-standard product available for rent. The Company’s cleanroom division serves the pharmaceutical, biotechnology, and manufacturing sectors by providing standard and customized pre-certified ISO and USP compliant units for lease and for sale. MDI is headquartered in Indianapolis, IN. About O2 Investment Partners O2 Investment Partners is a Midwestern based private equity firm that seeks to acquire majority interests in lower middle market B2B services, technology, and select industrial companies. The firm invests in businesses with earnings growth potential and a clear path to the creation of shareholder value. O2 invests with a view toward partnering with management to build and grow the business and take it to its next stage of development. This requires not only a clear vision and strategic plan to create shareholder value, but a close partnership and alignment of interest with management.

Read More

Spotlight

Every three seconds someone in the world develops dementia. Dementia affects 50 million people, costing the global economy over US$1 trillion in 2018. By 2030, there will be an estimated 82 million people with dementia, placing an unprecedented strain on health systems around the world.

Resources